2-Bromodeschloroketamine

2-Bromodeschloroketamine

Chemical structure of 2-Bromodeschloroketamine

2-Bromodeschloroketamine (BDCK) is a dissociative anesthetic and a derivative of ketamine. It is chemically related to 2-Fluorodeschloroketamine and 2-Chlorodeschloroketamine, differing by the presence of a bromine atom in place of a chlorine or fluorine atom.

Chemical Structure

2-Bromodeschloroketamine belongs to the arylcyclohexylamine class of compounds. Its structure is characterized by a cyclohexanone ring bonded to an aryl group and an amine group. The presence of the bromine atom distinguishes it from other ketamine analogs.

Pharmacology

2-Bromodeschloroketamine acts primarily as an NMDA receptor antagonist, similar to ketamine. This action is responsible for its dissociative effects, which include analgesia, anesthesia, and hallucinations. The bromine substitution may alter its potency, duration of action, and side effect profile compared to other ketamine analogs.

Uses

While ketamine is widely used in medicine for anesthesia and pain management, 2-Bromodeschloroketamine is primarily of interest in research settings. Its potential therapeutic applications are under investigation, particularly in the context of depression and neuropathic pain.

Safety and Side Effects

The safety profile of 2-Bromodeschloroketamine is not well-established. However, it is likely to share some side effects with ketamine, such as dizziness, nausea, and dissociation. The long-term effects of its use are unknown, and caution is advised in its handling and study.

Legal Status

The legal status of 2-Bromodeschloroketamine varies by country. In some jurisdictions, it may be classified as a controlled substance due to its structural similarity to ketamine and potential for abuse.

Related Compounds

• Ketamine
• 2-Fluorodeschloroketamine
• 2-Chlorodeschloroketamine
• Methoxetamine

Related Pages

• Dissociative anesthetic
• NMDA receptor antagonist
• Arylcyclohexylamine